NCT07023731Phase 1, phase 2Completed

A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation

Study sponsor: Arvinas Inc. · ARVN

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2026-10-30Actual
Enrollment · participants76Actual
Source updated2026-11-17Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.